Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (8922)	3/3/1999 10:49:00 PM
From: opalapril	Read Replies (1) \| Respond to of 17367

Relieved -- I think -- to see that the lights are still on, although it looks like a candle should be put in the window for Tharos and another for RobertK. Gosh, after all these years, a journey of almost Odyssian duration, and to give it up just a few miles from home! Someone asked if there was anything new in the revised Xoma FAQ. For what it's worth, there's nothing of substance that I could see except an interesting change of wording to the effect that if Neuprex is approved Xoma 'most likely' would market the compound by itself although a deal with a 'small' pharma cannot be ruled out as a possibility. Sorry I don't have the exact quote, but this is the sense of it. I certainly don't recall Xoma hinting around about a "small" partner before. This, I believe, is a new wrinkle. Also a very, very worrisome one. Seems we are to conclude that Xoma's once-trumpted efforts to hook up with a big pharma after more than two years of trying came to nothing and the company recognizes it is futile to continue pursuing the possibility. Read: Big pharmas have told us they don't think Neuprex will be approved or even if it is they want no part of it. Hard to justify staying in the stock after that vote of no confidence!